Immunotherapy against lung cancer does not need to compromise the outcomes of COVID-19
- PMID: 38163089
- PMCID: PMC10757045
- DOI: 10.1002/mco2.451
Immunotherapy against lung cancer does not need to compromise the outcomes of COVID-19
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Infections and Immunotherapy in Lung Cancer: A Bad Relationship?Int J Mol Sci. 2020 Dec 22;22(1):42. doi: 10.3390/ijms22010042. Int J Mol Sci. 2020. PMID: 33375194 Free PMC article. Review.
-
The impact of the COVID-19 pandemic on lung cancer patients.Ann Palliat Med. 2020 Sep;9(5):3373-3378. doi: 10.21037/apm-20-1662. Ann Palliat Med. 2020. PMID: 33065788
-
Hypermetabolic lymphadenopathy following the administration of COVID-19 vaccine and immunotherapy in a lung cancer patient: a case report.J Med Case Rep. 2022 Nov 25;16(1):445. doi: 10.1186/s13256-022-03660-9. J Med Case Rep. 2022. PMID: 36434709 Free PMC article.
-
Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey.BMC Cancer. 2023 Jun 30;23(1):603. doi: 10.1186/s12885-023-11074-z. BMC Cancer. 2023. PMID: 37386452 Free PMC article.
-
Natural killer cell‑based immunotherapy for lung cancer: Challenges and perspectives (Review).Oncol Rep. 2021 Nov;46(5):232. doi: 10.3892/or.2021.8183. Epub 2021 Sep 9. Oncol Rep. 2021. PMID: 34498710 Free PMC article. Review.
Cited by
-
Pan-cancer and multiomics: advanced strategies for diagnosis, prognosis, and therapy in the complex genetic and molecular universe of cancer.Clin Transl Oncol. 2025 Jul;27(7):2936-2954. doi: 10.1007/s12094-024-03819-4. Epub 2024 Dec 26. Clin Transl Oncol. 2025. PMID: 39725831 Review.
-
"Elucidating the immunomodulatory role of endocannabinoids in intervertebral disc degeneration".Eur Spine J. 2025 Jan;34(1):308-315. doi: 10.1007/s00586-024-08550-w. Epub 2024 Nov 14. Eur Spine J. 2025. PMID: 39542877
References
-
- World Health Organization . WHO coronavirus (COVID‐19) dashboard. Accessed September 27, 2023. https://covid19.who.int/
-
- Abbasi J. What to know about EG.5, the latest SARS‐CoV‐2 “Variant of Interest”. JAMA. 2023;b330(10):900‐901. - PubMed
-
- Tan Y, Tang F. SARS‐CoV‐2‐mediated immune system activation and potential application in immunotherapy. Med Res Rev. 2021;41(2):1167‐1194. - PubMed
LinkOut - more resources
Full Text Sources